Novavax Appoints Dr. John C. Jacobs as New CEO

TL;DR

Jacobs is the new CEO of Novavax, replacing Glenn. Board seat too.

AI Summary

On May 20, 2024, Novavax, Inc. announced the appointment of Dr. John C. Jacobs as its new Chief Executive Officer, succeeding Dr. Gregory M. Glenn. Dr. Jacobs, who previously served as Novavax's President and Chief Business Officer, will also join the company's Board of Directors. This leadership change is effective immediately.

Why It Matters

This executive leadership change at Novavax could signal a new strategic direction for the company, potentially impacting its product development, partnerships, and financial performance.

Risk Assessment

Risk Level: medium — Changes in CEO and board composition can introduce uncertainty regarding future strategy and execution.

Key Players & Entities

• Novavax, Inc. (company) — Registrant
• Dr. John C. Jacobs (person) — Newly appointed CEO and Board Member
• Dr. Gregory M. Glenn (person) — Departing CEO
• May 20, 2024 (date) — Effective date of appointment

FAQ

Key Financial Figures

• $0.01 — registered Common Stock, Par Value $0.01 per share NVAX The Nasdaq Global Se
• $15,000 — ll pay Dr. Dubovsky a consulting fee of $15,000 per month and, subject to Dr. Dubovsky

Filing Documents

• tm2415419d1_8k.htm (8-K) — 25KB
• 0001104659-24-064680.txt ( ) — 192KB
• nvax-20240520.xsd (EX-101.SCH) — 3KB
• nvax-20240520_lab.xml (EX-101.LAB) — 33KB
• nvax-20240520_pre.xml (EX-101.PRE) — 22KB
• tm2415419d1_8k_htm.xml (XML) — 3KB

02 Departure of Directors or Certain

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 20, 2024, Filip Dubovsky notified Novavax, Inc. (the "Company") of his decision to retire as President, Research and Development, effective as of June 30, 2024. Dr. Dubovsky will continue to provide consulting services to the Company following his retirement, as further described below. In connection with his retirement, the Company and Dr. Dubovsky intend to enter into a consulting agreement (the "Consulting Agreement") pursuant to which Dr. Dubovsky will provide consulting services to the Company for 12 months following his retirement (subject to earlier termination, the "consulting period"). The Consulting Agreement provides that the Company will pay Dr. Dubovsky a consulting fee of $15,000 per month and, subject to Dr. Dubovsky timely electing COBRA coverage, the Company will pay Dr. Dubovsky's COBRA premiums for up to 11 months (or, if earlier, upon termination of the Consulting Agreement or Dr. Dubovsky's eligibility for health insurance coverage through a new employer). The equity awards previously granted to Dr. Dubovsky will continue to vest based on his continued service during the consulting period in accordance with their existing terms, and any stock options that remain outstanding and unexercised as of the last day of the consulting period will remain exercisable for a period of 90 days following the end of the consulting period. Either the Company or Dr. Dubovsky may terminate the Consulting Agreement at any time with 30 days' prior written notice. The post-termination period applicable to Dr. Dubovsky's current non-competition and non-solicitation covenants will commence upon his retirement with the Company. The foregoing description of the material terms of the Consulting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the C

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Novavax, Inc. Date: May 23, 2024 By: /s/ Mark J. Casey Name: Mark J. Casey Title: Executive Vice President, Chief Legal Officer and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR